Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Using biologics safely.

Choy EH.

Rheumatology (Oxford). 2019 Apr 14. pii: kez129. doi: 10.1093/rheumatology/kez129. [Epub ahead of print] No abstract available.

PMID:
30982882
2.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

3.

Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT).

Hewlett S, Almeida C, Ambler N, Blair PS, Choy EH, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan JR, Plummer Z, Rooke C, Thorn J, Turner N, Pollock J; RAFT Study Group.

Ann Rheum Dis. 2019 Apr;78(4):465-472. doi: 10.1136/annrheumdis-2018-214469. Epub 2019 Feb 6.

4.

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam LS, Choy EH.

J Rheumatol. 2019 Feb 15. pii: jrheum.181054. doi: 10.3899/jrheum.181054. [Epub ahead of print]

PMID:
30770514
5.

The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Feb 11. [Epub ahead of print] Review.

PMID:
30767864
6.

Clinical significance of Janus Kinase inhibitor selectivity.

Choy EH.

Rheumatology (Oxford). 2019 Jun 1;58(6):1122. doi: 10.1093/rheumatology/kez002. No abstract available.

7.

Clinical significance of Janus Kinase inhibitor selectivity.

Choy EH.

Rheumatology (Oxford). 2019 Jun 1;58(6):953-962. doi: 10.1093/rheumatology/key339. Erratum in: Rheumatology (Oxford). 2019 Jun 1;58(6):1122.

8.

Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.

Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, Suarez-Almazor ME, Lyddiatt A, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2019 Jun;48(6):958-966. doi: 10.1016/j.semarthrit.2018.10.002. Epub 2018 Oct 9.

PMID:
30396592
9.

Functional MRI in rheumatic diseases with a focus on fibromyalgia.

Pamfil C, Choy EHS.

Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):82-85. Epub 2018 Oct 1. Review.

10.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM.

J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19.

11.

Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis.

Jordan LA, Erlandsson MC, Fenner BF, Davies R, Harvey AK, Choy EH, Errington R, Bokarewa MI, Williams AS.

Rheumatology (Oxford). 2018 Nov 1;57(11):2042-2052. doi: 10.1093/rheumatology/key196.

12.

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.

O'Mahony A, John MR, Cho H, Hashizume M, Choy EH.

J Transl Med. 2018 Jun 7;16(1):156. doi: 10.1186/s12967-018-1532-5.

13.

Corrigendum: Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Goff BL, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Tas SW, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Dec 19;14(1):60. doi: 10.1038/nrrheum.2017.206.

PMID:
29255214
14.

Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.

Choy EHS, Calabrese LH.

Rheumatology (Oxford). 2018 Nov 1;57(11):1885-1895. doi: 10.1093/rheumatology/kex391. Review.

15.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Sep 22;13(10):630. doi: 10.1038/nrrheum.2017.161.

PMID:
28935945
16.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.

Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.

17.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

PMID:
28811351
18.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ, Tas SW.

Nat Rev Rheumatol. 2017 Aug;13(8):463-475. doi: 10.1038/nrrheum.2017.115. Epub 2017 Jul 13. Review. Erratum in: Nat Rev Rheumatol. 2017 Sep 22;13(10 ):630. Nat Rev Rheumatol. 2017 Dec 19;14 (1):60.

PMID:
28701760
19.

Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.

Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1484-1494. doi: 10.1002/acr.23303. Epub 2017 Sep 6.

20.

EULAR recommendations for management of fibromyalgia.

Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy G, Makri S, Perrot S, Sarzi Puttini P, Taylor A, Jones GT.

Ann Rheum Dis. 2017 Dec;76(12):e54. doi: 10.1136/annrheumdis-2017-211587. Epub 2017 May 5. No abstract available.

PMID:
28476880
21.

Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice.

Sime K, Choy EH, Williams AS.

Adipocyte. 2017 Apr 3;6(2):87-101. doi: 10.1080/21623945.2017.1295174. Epub 2017 Feb 21.

22.

Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.

Tarp S, Furst DE, Dossing A, Østergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2017 Jun;46(6):699-708. doi: 10.1016/j.semarthrit.2016.09.003. Epub 2016 Sep 14. Review.

PMID:
27769592
23.

Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making.

Owen ED, Choy EH, Piguet V.

Br J Dermatol. 2016 Oct;175(4):665-6. doi: 10.1111/bjd.14917. No abstract available.

PMID:
27650736
25.

Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia.

Choy EH.

Pain Manag. 2016 May;6(4):339-46. doi: 10.2217/pmt-2016-0009. Epub 2016 Jun 17.

PMID:
27312978
26.

Biologic interventions for fatigue in rheumatoid arthritis.

Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, Pollock J, Christensen R.

Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008334. doi: 10.1002/14651858.CD008334.pub2. Review.

PMID:
27271314
27.

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ.

RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.

28.

Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.

Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, Clauw DJ, Gignac MA, Markman JD, Williams DA, Bujanover S, Burke LB, Carr DB, Choy EH, Conaghan PG, Cowan P, Farrar JT, Freeman R, Gewandter J, Gilron I, Goli V, Gover TD, Haddox JD, Kerns RD, Kopecky EA, Lee DA, Malamut R, Mease P, Rappaport BA, Simon LS, Singh JA, Smith SM, Strand V, Tugwell P, Vanhove GF, Veasley C, Walco GA, Wasan AD, Witter J.

Pain. 2016 Sep;157(9):1836-50. doi: 10.1097/j.pain.0000000000000577. Review.

29.

Ms. A.M. Taylor, et al reply.

Taylor AM, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2016 Apr;43(4):826. doi: 10.3899/jrheum.151456. No abstract available.

30.

Fibromyalgia: management strategies for primary care providers.

Arnold LM, Gebke KB, Choy EH.

Int J Clin Pract. 2016 Feb;70(2):99-112. doi: 10.1111/ijcp.12757. Review.

31.

The biology behind interleukin-6 targeted interventions.

Liu X, Jones GW, Choy EH, Jones SA.

Curr Opin Rheumatol. 2016 Mar;28(2):152-60. doi: 10.1097/BOR.0000000000000255. Review.

PMID:
26751841
32.

Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT.

Phillips K, Taylor A, Mease PJ, Simon LS, Conaghan PG, Choy EH, Singh JA, Strand V, Gossec L, Kaiser U, de Wit M, Ostelo R, Maxwell L, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1943-1946. doi: 10.3899/jrheum.141386. Epub 2015 Aug 1.

PMID:
26233508
33.

Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain.

Taylor AM, Phillips K, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2015 Oct;42(10):1947-1953. doi: 10.3899/jrheum.141328. Epub 2015 Jul 1.

PMID:
26136483
34.

Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial.

Dougados M, Huizinga TW, Choy EH, Bingham CO 3rd, Aassi M, Bernasconi C.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1762-6. doi: 10.1002/acr.22633.

35.

Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.

Humby F, Kelly S, Bugatti S, Manzo A, Filer A, Mahto A, Fonseca JE, Lauwerys B, D'Agostino MA, Naredo E, Lories R, Montecucco C, Tak PP, Fitzgerald O, Smith MD, Veale DJ, Choy EH, Strand V, Pitzalis C.

J Rheumatol. 2016 Jan;43(1):208-13. doi: 10.3899/jrheum.141199. Epub 2015 Jun 1. Review.

PMID:
26034155
36.

The role of sleep in pain and fibromyalgia.

Choy EH.

Nat Rev Rheumatol. 2015 Sep;11(9):513-20. doi: 10.1038/nrrheum.2015.56. Epub 2015 Apr 28. Review.

PMID:
25907704
37.

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, Furst DE, Guillemin F, Halls S, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Orbai AM, Pohl C, Voshaar MS, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2015 Nov;42(11):2185-9. doi: 10.3899/jrheum.141169. Epub 2015 Feb 15. Review.

38.

Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients.

Lipkovich IA, Choy EH, Van Wambeke P, Deberdt W, Sagman D.

BMC Musculoskelet Disord. 2014 Dec 23;15:450. doi: 10.1186/1471-2474-15-450.

39.

Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, Furst DE, Hewlett S, Leong AL, Lyddiatt A, March L, May JE, Montie P, Orbai AM, Pohl C, Scholte Voshaar M, Woodworth T, Bingham CO 3rd, Choy EH.

J Rheumatol. 2014 Apr;41(4):799-809. doi: 10.3899/jrheum.131252. Epub 2014 Mar 1. Review.

40.

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.

Choy EH, Bendit M, McAleer D, Liu F, Feeney M, Brett S, Zamuner S, Campanile A, Toso J.

Arthritis Res Ther. 2013 Sep 24;15(5):R132. doi: 10.1186/ar4312.

41.

Cognitive behavioural therapies for fibromyalgia.

Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W.

Cochrane Database Syst Rev. 2013 Sep 10;(9):CD009796. doi: 10.1002/14651858.CD009796.pub2. Review.

42.

Non-pharmacological interventions for fatigue in rheumatoid arthritis.

Cramp F, Hewlett S, Almeida C, Kirwan JR, Choy EH, Chalder T, Pollock J, Christensen R.

Cochrane Database Syst Rev. 2013 Aug 23;(8):CD008322. doi: 10.1002/14651858.CD008322.pub2. Review.

PMID:
23975674
43.

Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.

Lie E, Woodworth TG, Christensen R, Kvien TK, Bykerk V, Furst DE, Bingham CO 3rd, Choy EH; OMERACT RA Flare Working Group.

Ann Rheum Dis. 2014 Oct;73(10):1781-7. doi: 10.1136/annrheumdis-2013-203496. Epub 2013 Jul 12.

PMID:
23852690
44.

Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis.

Gullick NJ, Abozaid HS, Jayaraj DM, Evans HG, Scott DL, Choy EH, Taams LS.

Clin Exp Immunol. 2013 Nov;174(2):292-301. doi: 10.1111/cei.12167.

45.

Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy.

Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM.

Clin Exp Immunol. 2013 Oct;174(1):18-26. doi: 10.1111/cei.12161.

46.

The problem of choice: current biologic agents and future prospects in RA.

Choy EH, Kavanaugh AF, Jones SA.

Nat Rev Rheumatol. 2013 Mar;9(3):154-63. doi: 10.1038/nrrheum.2013.8. Epub 2013 Feb 19. Review.

PMID:
23419427
47.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

48.

Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Gordon PA, Winer JB, Hoogendijk JE, Choy EH.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD003643. doi: 10.1002/14651858.CD003643.pub4. Review.

PMID:
22895935
49.

Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus.

Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, Choy EH, Sanderson T, Boonen A, Bykerk V, Leong AL, Strand V, Furst DE, Christensen R; OMERACT RA Flare Working Group.

Ann Rheum Dis. 2012 Nov;71(11):1855-60. doi: 10.1136/annrheumdis-2011-201201. Epub 2012 Jul 6.

PMID:
22772326
50.

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective.

Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G.

J Med Econ. 2012;15(3):481-92. doi: 10.3111/13696998.2012.660254. Epub 2012 Feb 17. Review.

PMID:
22339078

Supplemental Content

Support Center